TB vaccine challenge study pulled before it began

NCT ID NCT06845358

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if the BCG vaccine, given as a skin injection, could stop the TB bacteria from growing in healthy adults. Researchers planned to vaccinate some volunteers and then expose them to a weakened form of TB six months later to measure protection. However, the trial was withdrawn before any volunteers were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BCG TICE strain (a live, weakened tuberculosis vaccine)

What this could lead to

If successful, this study could help researchers understand how well the BCG vaccine protects against TB infection, potentially guiding future vaccine development.

What could go wrong

This trial was withdrawn before any participants enrolled, so no data was collected. The approach is very early-stage and may not translate to real-world protection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.